Skip to main content

ARA-290 vs Dihexa

Both ARA-290 and Dihexa are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

ARA-290

Evidence B

ARA-290 (Cibinetide)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

View full ARA-290 profile →

Dihexa

Evidence C

Dihexa (PNB-0408)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

View full Dihexa profile →

Side-by-Side

AttributeARA-290Dihexa
Evidence GradeBC
FDA StatusNot FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathyNot FDA-approved — research compound (HGF/c-Met-mimetic)
Typical DoseTrial range: 1–4 mg subcutaneous daily8–45 mg orally daily (research-only)
Clinics Indexed910
Categoriesanti-inflammatory, neuroprotectioncognitive, neuroprotection

Key reported benefits — ARA-290

  • Small-fiber neuropathy improvement
  • Anti-inflammatory
  • No erythrocytosis

Key reported benefits — Dihexa

  • Synaptogenesis (preclinical)
  • Memory improvement (animal)
  • Possible Alzheimer's relevance

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons